Congestive heart failure in Indians: How do we improve diagnosis & management?

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 549-560

  Reddy, S ^a   Bahl, A ^a   Talwar, K K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Brain natriuretic peptide; Device therapy; Drug therapy; Heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CARVEDILOL; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; EPLERENONE; ERYTHROPOIETIN; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; METOPROLOL; NEBIVOLOL; NITROPRUSSIDE SODIUM; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ACUTE HEART FAILURE; ALGORITHM; ALKALOSIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTICOAGULATION; AORTA BALLOON; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL THERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; DEFIBRILLATOR; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIET; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIURETIC THERAPY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; FATIGUE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE ASSIST DEVICE; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HEART TRANSPLANTATION; HEART VALVE SURGERY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INDIA; LABORATORY TEST; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NEPHROTOXICITY; NON INVASIVE POSITIVE PRESSURE VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; NUTRITIONAL DEFICIENCY; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; REVIEW; RISK FACTOR; SOCIAL SUPPORT; TELEMEDICINE; TELEMONITORING; TERTIARY HEALTH CARE; THORAX RADIOGRAPHY; THYROID DISEASE; TREATMENT OUTCOME; VALVULAR HEART DISEASE; BLOOD; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; INCIDENCE; METHODOLOGY; PREVALENCE;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; DISEASE MANAGEMENT; DIURETICS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HUMANS; INCIDENCE; INDIA; MAGNETIC RESONANCE IMAGING; NATRIURETIC PEPTIDE, BRAIN; PREVALENCE;

EID: 78649483342     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-171.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18.
3. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004; 88: 1145-72.
4. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D ́Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-72.
5. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 320-32.
6. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002; 39: 138-41.
7. Brutsaert DL, Sys SU. Diastolic dysfunction in heart failure. J Card Fail 1997; 3: 225-42.
8. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101: 2118-21.
9. Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001; 38: 1277-82.
10. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? JAMA 1997; 277: 1712-9.
11. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002; 112: 437-45.
12. Ghali JK, Kadakia S, Cooper RS, Liao YL. Bedside diagnosis of preserved versus impaired left ventricular systolic function in heart failure. Am J Cardiol 1991; 67: 1002-6.
13. Harlan W R, Oberman A, Grimm R, Rosati RA. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med 1977; 86: 133-8.
14. Marantz PR, Tobin JN, Wassertheil-Smoller S, Wexler JP, Budner N, Lense L, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 1988; 77: 607-12.
15. Gadsbøll N, Høilund-Carlsen PF, Nielsen GG, Berning J, Brunn NE, Stage P. Symptoms and signs of heart failure in patients with myocardial infarction: reproducibility and relationship to chest x-ray, radionuclide ventriculography, and right heart catheterization. Eur heart J 1989; 10: 1017-28.
16. Chakko S, Woska D, Martinez H, De Marchena E, Futterman L, Kessler KM, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure. Conflicting results may lead to inappropriate care. Am J Med 1991; 90: 353-9.
17. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884-8.
18. Ewy GA. The abdominaljugular test: techinique and hemodynamic correlates. Ann Intern Med 1988; 109: 456-60.
19. Butman S M, Ewy GA, Standen JR, Kern KB, Hahn E. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest of inducible jugular venous distension. J Am Coll Cardiol 1993; 22: 968-74.
20. Zema MJ, Restivo B, Sos T, Sniderman KW, Kline S. Left ventricular dysfunction: bedside Valsalva manoeuvre. Br Heart J 1980; 44: 560-9.
21. Hunt S, Abraham W, Chin M, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005; 46: 1116-43.
22. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002; 143: 1085-91.
23. Kalra PR, Sharma R, Shamim W, Doehner W, Wensel R, Bolger AP, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol 2002; 86: 225-31.
24. Baldasseroni S, Gentile A, Gorini M, Marchionni M, Marini M, Massotti G, et al. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). Ital Heart J 2003; 4: 607-13.
25. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni M, Marini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143: 398-405.
26. Shenkman HJ, Pampati V, Khandelwal AK, MacKinnon J, Nori D, Katz S, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002; 122: 528-34.
27. Knudsen CW, Omland T, Clopton P, Westheim A, Abraham T, Storrow AB, et al. Diagnostic value of B-Type Natriuretic Peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116: 363-8.
28. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004; 55: 373-94.
29. Vinch CS, Aurigemma GP, Hill JC, Gaasch WH, Voltuvo G, Tighe DA, et al. Usefulness of clinical variables, echocardiography, and levels of brain natriuretic peptide and norepinephrine to distinguish systolic and diastolic causes of acute heart failure. Am J Cardiol 2003; 91: 1140-3.
30. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997; 30: 8-18.
31. Garcia MJ, Rodriguez L, Ares M, Griffin BP, Thomas JD, Klein AL, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. J Am Coll Cardiol 1996; 27: 108-14.
32. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Levine, et al. The role of endomyocardial biopsy in the management of cardiovascular disease A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol 2007; 50: 1914-31.
33. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
34. Maise AS, Krishnaswamy P, Nowak RM, Mac Cord J, Hollander JE, Duc P, et al; for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
35. McCullough PA, Nowak RM, McCord J, Hollander JE, Hermann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (bnp) multinational study. Circulation 2002; 106: 416-22.
36. Collins SP, Ronan-Bentle S, Storrow AB. Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnoea. Ann Emerg Med 2003; 41: 532-45.
37. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-38.
38. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007; 50: 205-14.
39. Fang XH, Kronmal RA, Li SC, Longstreth WT Jr, Cheng XM, wang W, et al. Prevention of stroke in urban China; a community-based intervention trial. Stroke 1999; 30: 495-501.
40. Puska P. Successful prevention of non-communicable diseases: 25 year experiences with North Karelia Project in Finland. Public Health Med 2002; 4: 5-7.
41. Fortmann SP, Williams PS, Hulley SB, Haskell WL, Farquahar JW. Effect of health education on dietary behavior: Stanford Three Community Study. Am J Clin Nutr 1981; 34: 2030-8.
42. Fortmann SP, Flora JA, Winkleby MA, Schooler C, Baylor CB, Farquhar JW. Community Intervention Trials: Reflections on the Stanford Five-City Project Experience. Am J Epidemiol 1995; 142: 5876-8.
43. Luepker RV, Murray DM, Jacobs DR, Mittelmark MB, Bracht N, Carlaw R, et al. Community Education for Cardiovascular Disease Prevention: Risk Factor Changes in the Minnesota Heart Health Program. Am J Public Health 1994; 84: 1383-93.
44. Volaklis KA, Tokmakidis SP. Resistance training in patients with heart failure. Sports Med 2005; 35: 1085-103.
45. Pu CT, Johnson MT, Forman DE, Hausdorff JM, Roubenoff R, Foldvari M, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 2001; 90: 2341-50.
46. Piña IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, et al. Committee on Exercise, Rehabilitation, and Prevention. Exercise and heart failure: a statement from the American Heart Association. Circulation 2003; 107: 1210-25.
47. Ramirez EC, Martinez LC, Tejeda AO, Gonzalez VR, David RN, Lafuente EA. Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. Nutrition 2004; 20: 890-5.
48. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-95.
49. Hariman RJ, Bremmer S, Louie EM, Rogers WJ, Kostis JB, Nocero MA, et al. Dose response study of intravenous torsemide in congestive heart failure. Am Heart J 1994; 128: 352-7.
50. [No authors listed]. MERIT-HF Study Group, Effect of metoprolol CR/XxL in chronic heart failure: metoprolol CR/Randomised Intervention Trial in Congestive heart failure (MERIT-HF) Lancet 1999; 353: 2001-7.
51. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
52. [No authors listed]. CIBIS Investigators and Committees, A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
53. [No authors listed]. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
54. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
55. Talwar KK, Bhargava B, Upasani P, Verma S, Kamlakar T, Chopra P. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Card Fail 1996; 2: 273-7.
56. Givertz MM. Manipulation of the rennin angiotensin system. Circulation 2001; 104: e14-e-18.
57. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
58. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
59. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991; 325: 303-10.
60. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-8.
61. Pfeffer MA, Braunwald E, Moyé L, Basta LA, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
62. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
63. Kober L, Torp-Pedersen C, Carlsen JE, et al (TRACE study group). A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
64. Ambrosioni E, Boghi C, Magnani B for the Survival of Myocardila Infarction Long-term evaluation study investigators. The effect of the angiotensin - converting- enzyme inhibitor zofenopril on mortality and morbidity after myocardial infarction. N Engl J Med 1995; 332: 80-5.
65. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al; the CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-35.
66. Erdmann E, George M, Voet B, Belcher G, Kolb D, Hiemstra S et al. The safety and tolerability of candesartan cilexetil in CHF. J Renin-Angiotensin Aldosterone Syst 2000; 1: 31-6.
67. Sharma D, Buyse M, Pitt B, Rucinska EJ for the Losartan Heart Failure Mortality Meta-analysis Study Group. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Am J Cardiol 2000; 85: 187-92.
68. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
69. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
70. McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting- enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
71. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al; for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
72. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
73. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
74. Packer M, Gheorghiade M, Young JB, Constatini PJ, Adams KF,Cody RJ, et al. The RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
75. [No authors listed]. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336: 525-33.
76. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorigiade, Greenberg BH, et al. OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007; 297: 61-70.
77. Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Guize L, Alla F, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006; 8: 697-705.
78. Chatti R, Fradj N, Trabelsi W, Kechiche H, Tavares M, Mebazza A. Algorithm for therapeutic management of acute heart failure syndromes. Heart Fail Rev 2007; 12: 113-7.
79. Strickberger SA, Conti J, Daoud EG, Havranek E, Mehra MR, Pina IL, et al. Patient selection for cardiac resynchronization therapy from the council on clinical cardiology subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 2005; 111: 2146-50.
80. Cleland J, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. For the Cardiac Resynchronisation- Heart Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
81. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, et al. Cardiac resynchronization and death from progressive heart failure. A Meta-analysis of Randomized Controlled Trials. JAMA 2003; 289:730-40.
82. Freemantle N, Tharmanathan P, Calvert MJ, Abraham WT, Ghosh J, Cleland JG. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction- a systematic review and meta-analysis. Eur J Heart Fail 2006; 8: 433-40.
83. Moss AJ, Zareba W, Hall J, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
84. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. N Engl J Med 2005; 352: 225-37.
85. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, Marco TD, et al. For the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
86. Stone ME. Current status of mechanical circulatory assistance. Semin Cardiothorac Vasc Anesth 2007; 11: 185-204.
87. Hunt SA, Rider AK, Stinson EB, Griepp RB, Schroeder JS, Harrison DC, et al. Does cardiac transplantation prolong life and improve its quality? An updated report. Circulation 1976; 54: III56-60.
88. Deng MC, Smits JM, Yopung JB. Proposition: the benefit of cardiac transplantation in stable outpatients with heart failure should be tested in a randomized trial. J Heart Lung Transplant 2003; 22: 113-7.
89. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa ALS, Mesquita TS, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-2302.
90. Smits PC, van Geuns RJ, Poldermans D, Bountioukos, Onderwater EM, Lee CH, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003; 42: 2063-9.
91. Seth S, Narang R, Bhargava B, Ray R, Mohanty S, Gulati G, et al. AIIMS Cardiovascular Stem Cell Study Group. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J Am Coll Cardiol 2006; 48: 2350-1.
92. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17.
93. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-8.
94. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-5.
95. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-21.